NES ZIONA, Israel--(BUSINESS WIRE)--OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced at the European Congress for Perinatal Medicine (ECPM), held in Paris, France at June 13-16, results of a successful clinical trial using NBM200, a non-invasive hemoglobin (Hb) measurement system for anemia screening and hemorrhage detection. Dr. Eran Hadar, of the Department of Maternal Fetal Medicine at Rabin Medical Center, Israel, presented results showing that OrSenes's device was as accurate as invasive point of care (POC) devices in measuring Hb levels in pregnant women.
